Sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease without and after kidney transplantation

Česká verzia

Authors: Patrícia Kleinová ^1,2; Tímea Blichová ^1,2; Matej Vnučák ^1,2; Karol Graňák ^1,2; Monika Beliančinová ^1,2; Ivana Dedinská ^1,2
Authors place of work: Transplantačno-nefrologické oddelenie UNM, Martin ¹; I. interná klinika JLF UK a UNM, Martin ²
Published in the journal: Forum Diab 2024; 13(2): 69-72
Category: Review Article

Summary

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent the first-line treatment for diabetic kidney disease, and have also become part of the treatment algorithm for chronic kidney disease. Gliflozin have significant cardio-renoprotective effects with reduction of albuminuria and stabilization of glomerular filtration rate in patients with chronic kidney disease. Secondary effects (weight reduction, stimulation of erythropoiesis, inhibition of pro-inflammatory parameters) make SGLT2i broad-spectrum agents with the possibility of expanding prescribing restrictions. However, the benefit and safety of use in patients after kidney transplantation remains a question.

Keywords:

kidney transplantation – chronic kidney disease (CKD) – sodium-glucose cotransporter 2 inhibitors (SGLT2i)

Zdroje

Mark PB, Sarafidis P, Ekart R et al. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrol Dial Transplant 2023; 38(11): 2444–2455. Dostupné z DOI: <http://dx.doi.org/10.1093/ndt/gfad112>.

Ehrenkranz JR, Lewis NG, Kahn CR et al. Phlorizin: a review. Diabetes Metab Res Rev 2005; 21(1): 31–38. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.532>.

Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors. [Updated 03–06–2023]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Dostupné z WWW: <https://www.ncbi.nlm.nih.gov/books/NBK576405/>.

Skrabic R, Kumric M, Vrdoljak J et al. SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice. Biomedicines 2022; 10(10): 2458. Dostupné z DOI: <http://dx.doi.org/10.3390/biomedicines10102458>.

Rossing P, Caramori ML, Chan JCN et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int 2022; 102(5): 990–999. Dostupné z DOI: <http://dx.doi.org/10.1016/j.kint.2022.06.013>.

Demir ME, Özler TE, Merhametsiz Ö et al. The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers. Int Urol Nephrol 2023; 55(11): 2989–2999. Dostupné z DOI: <https://doi.org/10.1007/s11255–023–03645–7>.

Sánchez Fructuoso AI, Bedia Raba A, Banegas Deras E et al. Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study. Clin Kidney J 2023; 16(6): 1022–1034. Dostupné z DOI: <https://doi.org/10.1093/ckj/sfad007>.

Fonseca-Correa JI, Correa-Rotter R. Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front Med (Lausanne) 2021; 8: 777861. Dostupné z DOI: <http://dx.doi.org/10.3389/fmed.2021.777861>.

Zinman B, Wanner C, Lachin JM et al. [EMPA-REG OUTCOME Investigators]. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.

August P. Chronic Kidney Disease – Another Step Forward. N Engl J Med 2023; 388(2): 179–180. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMe2215286>.

Heerspink HJ, Stefánsson BV, Correa-Rotter R et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383(15): 1436–1446. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2024816>.

Perkovic V, Jardine MJ, Neal B et al. [CREDENCE Trial Investigators]. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380(24): 2295–2306. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1811744>.

Herrington WG, Staplin N, Wanner C et al. [The EMPA-KIDNEY Collaborative Group]. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388(2): 117–127. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2204233>.

Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375(4):323–334. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1515920>.

Zoznam kategorizovaných liekov 1. 9. 2023–30. 9. 2023. [21–03–2024]. Dostupné z WWW: <https://www.health.gov.sk/?zoznam-kategorizovanych-liekov>.

Ramakrishnan P, Garg N, Pabich S et al. Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients. World J Transplant 2023; 13(5): 239–249. Dostupné z DOI: <http://dx.doi.org/10.5500/wjt.v13.i5.239>.

Ujjawal A, Schreiber B, Verma A. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence? Ther Adv Endocrinol Metab 2022; 13: 20420188221090001. Dostupné z DOI: <http://dx.doi.org/10.1177/20420188221090001>.

[Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group]. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International 2024; 105(Suppl 4S): S117–S314. Dostupné z DOI: <http://dx.doi.org/0.1016/j.kint.2023.10.018>.